{"pub": "reuters", "url": "https://reuters.com/article/us-china-biologic-m-a/china-biologic-receives-4-59-billion-take-private-buyout-offer-idUSKBN1W32Y1", "downloaded_at": "2019-09-18 23:29:00.096890+00:00", "title": "China Biologic receives $4.59 billion take-private buyout offer", "language": "en", "text": "(Reuters) - China Biologic Products Holdings Inc (CBPO.O) said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers.\n\nShares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.\n\nThe offer of $120 per share represents a premium of 16.3% to China Biologic\u2019s Wednesday close of $103.10.\n\nThe buyer group includes Beachhead Holdings Ltd, CITIC Capital China Partners IV LP, PW Medtech Group Ltd, Parfield International Ltd, HH Sum-XXII Holdings Ltd and V-Sciences Investments Pte Ltd. (reut.rs/2mnFvlQ)\n\nIn August 2018, China Biologic rejected a $3.9 billion offer from a consortium led by its former chief executive officer. (reut.rs/2BKMZXo)", "description": "China Biologic Products Holdings Inc said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "published_at": "2019-09-18"}